PATHSEC-BCA-BM

Pathway-based Secretomes in Breast Cancer Biomarker Discovery

Coordinatore	FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON    more  Organization address city: Barcelona postcode: 8035 contact info Titolo: Ms. Nome: Sandra Cognome: Porta Email: send email Telefono: 34932746026 Fax: 34934893884
Nazionalità Coordinatore	Spain [ES]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-RG
Funding Scheme	MC-IRG
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-05-01   -   2014-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON  Organization address city: Barcelona postcode: 8035 contact info Titolo: Ms. Nome: Sandra Cognome: Porta Email: send email Telefono: 34932746026 Fax: 34934893884	ES (Barcelona)	coordinator	100˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Improvements in the characterization of human tumors have resulted in better survival rates for cancer patients. However, less progress has been made in the development of clinical tools to monitor the course of the disease. Tumor markers have not had a broad acceptance in the clinical community, because the few that are known are organ rather than tumor specific. Proteomics biomarker discovery research is usually a brute-force effort, and suffers from lack of reproducibility and high biological sample complexity. There is need for proteomics hypothesis-driven biomarker discovery approaches that incorporate technology advances with understanding cancer at the molecular level. I propose a biomarker discovery approach that combines exploiting the tumor cell’s communication with its microenvironment and with the rest of the organism, with a proteomics method designed to specifically measure secreted proteins (the ‘secretome’). My hypothesis is that signaling pathways are altered during tumorigenesis, and that these alterations are translated into protein differential secretion, which potentially can be used to discover secreted markers. The strategy proposed entails generating breast cancer secretome signatures and mine them to discover secreted pathway-based biomarkers. There is great hope that the discovery of pathway-based biomarkers in breast cancer secretomes will facilitate individualized diagnostics and treatment of breast cancer patients.'